NCT03347370 - A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis | Biotech Hunter

Enrollment

626

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

DRUG

SC Peginterferon beta-1a

All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).

DRUG

SC interferon beta-1a

All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product characteristics \[SmPC\]).

DRUG

SC interferon beta-1b

All participants will be treated with their current SC interferon beta medication according to the Fachinformation (German equivalent to summary of product.

Trial Locations (1)

37073

Research Site, Göttingen